Noticias > Portada

Noticias

28/06/2018

Knowledge transfer from Basic Liver Research to NASH Drug Therapy Research

Galmed Pharmaceuticals recently announced that their lead NASH drug candidate, Aramchol, had achieved an FDA- regulatory-approvable endpoint demonstrating NASH resolution in the Aramchol Phase 2b, 52-week ARREST trial. Aramchol is a conjugate of cholic acid and arachidic acid, a first-in-class member of a novel family of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). These positive results mean that this new drug is on track for Phase III initiation and further clinical evaluation of its efficacy in NASH.

Newly-published studies further underscore the value of novel, non-invasive testing in patients with NASH

12/06/2018

Newly-published studies further underscore the value of novel, non-invasive testing in patients with NASH

As part of the First International NASH Day, OWL Metabolomics proudly announces the very recent publication of 3 scientific papers that specifically evaluate the utility of metabolomics-based laboratory testing in a variety of non-alcoholic steatohepatitis (NASH) clinical applications.

Consulte histórico de noticias

ONE WAY LIVER, S.L
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - España
Teléfono:
+34 94 431 85 40

A través de su web, OWL pretende contribuir a la divulgación de la ciencia y a la mejora de la salud y el bienestar de las personas. El carácter de la web es
meramente divulgativo y en ningún caso puede sustituir la relación médico-paciente. Ante cualquier duda, acuda a su centro médico o especialista.
Última actualización: 09/07/2018

Con la colaboración de: